GET THE APP

Genome biomarkers of prostate cancer | 49056

Oncology & Cancer Case Reports

ISSN - 2471-8556

Genome biomarkers of prostate cancer

15th World Congress on CANCER THERAPY, BIOMARKERS & CLINICAL RESEARCH

December 05-07, 2016 Philadelphia, USA

Jianhua Luo

University of Pittsburgh School of Medicine, USA

Keynote: Oncol Cancer Case Rep

Abstract :

Accurate prediction of prostate cancer clinical courses remains elusive. In recent studies, we performed whole genome analysis on prostate cancers by combining Affymetrix SNP6.0 chip, whole genome sequencing and transcriptome sequencing. Our results showed that combination of genome copy number variance and novel fusion transcripts specific for cancer achieved high accuracy in predicting prostate cancer outcomes. The prediction model was further improved when these molecular criteria were combined with Nomogram or Gleason├ó┬?┬?s grading, leukocyte CNV. Interestingly, some of these fusion genes are also present in a variety of human malignancies. Some of these fusion genes play critical roles in developing malignancies. Critical signaling pathways associated with some of these fusion genes have been characterized. Targeting at fusion gene appears to be an effective approach in killing cancer cells both in vitro and in vivo, and holds promise as a new treatment for human malignancies.

Biography :

Dr. Luo has been studying molecular pathology related to human malignancies in the last 24 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 16 years, Dr. Luo has been largely focusing on genetic and molecular mechanism of human prostate and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MT1h and GPC3. He has characterized several signaling pathways that play critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3, CSR1- SF3A3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 egigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, AR-MCM7 and MCM7-SF3B3 oncogenic pathways. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, Dr. Luo’s group found that the patterns of copy number variants of certain specific genome loci are predictive of prostate cancer clinical outcomes, regardless tissue origin. His discovery of several novel fusion transcripts and their association with aggressive prostate cancer has brought significant new insight into the field of prostate cancer research. Overall, these findings advance our understanding on how cancer develops and behaves, and lay down the foundation for better future diagnosis and treatment of human malignancies.

Email: luoj@msx.upmc.edu

Top